Medigrowth is an Australian-owned medicinal cannabis biotech focussed on translational research for the development of TGA registered cannabinoid medicines.
Medigrowth distributes pharmaceutical grade AU GMP medicinal cannabis products alongside multi sector industry and University engagement. Since establishment in 2017, Medigrowth has maintained its steadfast commitment to collaboration & clinical advancement in understanding of cannabinoid medicines.
With a number of clinical initiatives underway including investigation of cannabinoid medicines in paediatric autism & oncology, Medigrowth is excited to further develop translational research utilising world class technologies within the ARC Training Centre for Biomedical Analysis.
Adam is motivated by the challenge of creating impact with integrity in a dynamic new frontier of science & medicine.
Further information can be found at www.medigrowth.com.au & telehealth at www.haiku.health
